(oxo-pyrazolo1,5apyrimidin-2-yl)alkyl-carboxamides
CA 2441926 A1 · Owner: Neurogen Corporation · Inventors: Li, Guiying; Peterson, John M.; Albaugh, Pamela
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds of the formula: (I) and the pharmaceuticallz , acceptable salts thereof where the variables R1 R2, A, R4, R5, R6, R6', n, and W are defined herein. These compounds bind to the benzodiazepine site of GABAA receptors are provided and, therefore can be used to modulate ligand binding to GABAA receptors in vivo or in vitro and are particularly useful in , the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.